JP2017517506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017517506A5 JP2017517506A5 JP2016568497A JP2016568497A JP2017517506A5 JP 2017517506 A5 JP2017517506 A5 JP 2017517506A5 JP 2016568497 A JP2016568497 A JP 2016568497A JP 2016568497 A JP2016568497 A JP 2016568497A JP 2017517506 A5 JP2017517506 A5 JP 2017517506A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- heavy chain
- light chain
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 239000000556 agonist Substances 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 102000009410 Chemokine receptor Human genes 0.000 claims 3
- 108050000299 Chemokine receptor Proteins 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 208000037844 advanced solid tumor Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000037843 metastatic solid tumor Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462001534P | 2014-05-21 | 2014-05-21 | |
| US62/001,534 | 2014-05-21 | ||
| PCT/US2015/031081 WO2015179236A1 (en) | 2014-05-21 | 2015-05-15 | Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017517506A JP2017517506A (ja) | 2017-06-29 |
| JP2017517506A5 true JP2017517506A5 (enExample) | 2018-07-12 |
Family
ID=53284562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568497A Pending JP2017517506A (ja) | 2014-05-21 | 2015-05-15 | 癌を処置するための抗ｃｃｒ４抗体および４−１ｂｂアゴニストの併用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10023649B2 (enExample) |
| EP (1) | EP3145956A1 (enExample) |
| JP (1) | JP2017517506A (enExample) |
| KR (1) | KR20170004006A (enExample) |
| CN (1) | CN106413751A (enExample) |
| AU (1) | AU2015264528A1 (enExample) |
| BR (1) | BR112016026993A2 (enExample) |
| CA (1) | CA2949214A1 (enExample) |
| IL (1) | IL248540A0 (enExample) |
| MX (1) | MX2016015181A (enExample) |
| RU (1) | RU2016146993A (enExample) |
| WO (1) | WO2015179236A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| KR20180103150A (ko) * | 2016-01-25 | 2018-09-18 | 화이자 인코포레이티드 | 암을 치료하기 위한 ox40 작용제 및 4-1bb 작용제 단클론 항체의 조합 |
| NZ789594A (en) | 2016-06-20 | 2025-07-25 | Kymab Ltd | Anti-PD-L1 antibodies |
| EP3544601B1 (en) * | 2016-11-23 | 2024-03-20 | Translational Drug Development, LLC | A composition comprising a benzamide and a tnfrsf agonist binding to 4-1bb or gitr, and the use thereof in the treatment of cancer. |
| EP4032911A1 (en) | 2017-01-06 | 2022-07-27 | Eutilex Co., Ltd. | Anti-human 4-1bb antibodies and use thereof |
| ES2863412T3 (es) | 2017-03-29 | 2021-10-11 | Shionogi & Co | Composición farmacéutica para el tratamiento del cáncer |
| JP7657023B2 (ja) | 2017-06-09 | 2025-04-04 | プロビデンス ヘルス アンド サービシーズ－オレゴン | がんの処置のための腫瘍反応性ヒトｔ細胞の同定のためのｃｄ３９およびｃｄ１０３の使用 |
| MY202336A (en) * | 2017-07-11 | 2024-04-24 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
| CN109651507B (zh) | 2017-10-12 | 2021-11-26 | 瑞阳(苏州)生物科技有限公司 | 一种激动型4-1bb单克隆抗体 |
| WO2019072274A1 (zh) * | 2017-10-12 | 2019-04-18 | 瑞阳(苏州)生物科技有限公司 | 一种激动型4-1bb单克隆抗体 |
| WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
| WO2019090272A1 (en) | 2017-11-06 | 2019-05-09 | Flx Bio, Inc. | Chemokine receptor modulators for treatment of epstein barr virus positive cancer |
| EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| WO2019109238A1 (en) | 2017-12-05 | 2019-06-13 | Lyvgen Biopharma Co., Ltd. | Anti-cd137 antibodies and uses thereof |
| WO2019141268A1 (zh) * | 2018-01-22 | 2019-07-25 | 江苏恒瑞医药股份有限公司 | 抗4-1bb抗体、其抗原结合片段及其医药用途 |
| ES2998140T3 (en) * | 2018-03-13 | 2025-02-19 | Hoffmann La Roche | Therapeutic combination of 4-1bb agonists with anti-cd20 antibodies |
| EP3773720A4 (en) | 2018-04-10 | 2022-01-05 | Wuxi Biologics (Shanghai) Co. Ltd. | MONOCLONAL ANTIBODY AGAINST HUMAN 4-1BB, ITS PREPARATION PROCESS, AND ITS USE |
| CA3103629A1 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| WO2020023556A1 (en) | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of anti-cd137 antibody drug conjugate (adc) in allogeneic cell therapy |
| MX2021012961A (es) | 2019-04-24 | 2021-11-25 | Heidelberg Pharma Res Gmbh | Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos. |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| AU2020276500A1 (en) | 2019-05-10 | 2021-12-16 | Lyvgen Biopharma Holdings Limited | Humanized anti-CD137 antibodies and uses thereof |
| WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| JP2023511277A (ja) * | 2020-01-13 | 2023-03-17 | サイトダイン インコーポレイテッド | Ｃｃｒ５陽性の転移性のがんの処置のためのｃｃｒ５結合剤 |
| JP2023513896A (ja) * | 2020-02-04 | 2023-04-04 | ジェンマブ エー／エス | 療法において使用するための抗体 |
| TWI832035B (zh) | 2020-02-14 | 2024-02-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| EP4172323A1 (en) | 2020-06-29 | 2023-05-03 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| JP2023545444A (ja) * | 2020-10-13 | 2023-10-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 膵管腺癌を処置するための併用免疫療法および組成物 |
| KR20230165276A (ko) | 2021-03-31 | 2023-12-05 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도 |
| EP4351595A1 (en) | 2021-06-07 | 2024-04-17 | Providence Health & Services - Oregon | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
| JP2024525475A (ja) | 2021-06-29 | 2024-07-12 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | タノトランスミッションを促進するように操作された免疫細胞及びその使用 |
| MX2024000611A (es) | 2021-07-14 | 2024-02-02 | Genentech Inc | Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso. |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| ATE477273T1 (de) | 1998-12-01 | 2010-08-15 | Facet Biotech Corp | Humanisierte antikoerper gegen gamma-interferon |
| CN1296960A (zh) * | 1999-11-22 | 2001-05-30 | 上海博容基因开发有限公司 | 一种新的多肽——人ccr4相关蛋白31和编码这种多肽的多核苷酸 |
| CN100430420C (zh) | 2001-08-31 | 2008-11-05 | 协和发酵工业株式会社 | 人cdr-移植抗体及其抗体片段 |
| JP2005536511A (ja) * | 2002-07-15 | 2005-12-02 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | ４−１ｂｂ結合物質を用いる治療及び予防 |
| DE602004029934D1 (de) | 2003-12-04 | 2010-12-16 | Kyowa Hakko Kirin Co Ltd | Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament |
| GB0409799D0 (en) * | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| EP1827487A2 (en) | 2004-11-17 | 2007-09-05 | Board of Regents, The University of Texas System | Cancer immunotherapy incorporating p53 |
| EP2399935A3 (en) * | 2005-02-15 | 2012-02-22 | GTC Biotherapeutics, Inc. | An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof |
| WO2006129163A1 (en) | 2005-06-03 | 2006-12-07 | Pfizer Products Inc. | Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer |
| WO2009086514A1 (en) | 2007-12-28 | 2009-07-09 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| CN105481983B (zh) | 2010-09-09 | 2021-09-03 | 辉瑞公司 | 4-1bb结合分子 |
| MX361929B (es) | 2010-11-19 | 2018-12-19 | Eisai R&D Man Co Ltd Star | Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes. |
-
2015
- 2015-05-15 AU AU2015264528A patent/AU2015264528A1/en not_active Abandoned
- 2015-05-15 RU RU2016146993A patent/RU2016146993A/ru not_active Application Discontinuation
- 2015-05-15 CA CA2949214A patent/CA2949214A1/en not_active Abandoned
- 2015-05-15 WO PCT/US2015/031081 patent/WO2015179236A1/en not_active Ceased
- 2015-05-15 JP JP2016568497A patent/JP2017517506A/ja active Pending
- 2015-05-15 US US15/312,515 patent/US10023649B2/en not_active Expired - Fee Related
- 2015-05-15 KR KR1020167035347A patent/KR20170004006A/ko not_active Withdrawn
- 2015-05-15 BR BR112016026993A patent/BR112016026993A2/pt not_active Application Discontinuation
- 2015-05-15 EP EP15727159.4A patent/EP3145956A1/en not_active Withdrawn
- 2015-05-15 CN CN201580027437.7A patent/CN106413751A/zh active Pending
- 2015-05-15 MX MX2016015181A patent/MX2016015181A/es unknown
-
2016
- 2016-10-27 IL IL248540A patent/IL248540A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017517506A5 (enExample) | ||
| Suurs et al. | A review of bispecific antibodies and antibody constructs in oncology and clinical challenges | |
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
| JP2017516775A5 (enExample) | ||
| MX2024015039A (es) | Composiciones anti-cd24 y usos de las mismas | |
| JOP20200292A1 (ar) | Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان | |
| JP2017048208A5 (enExample) | ||
| JP2017510661A5 (enExample) | ||
| BRPI0918178A8 (pt) | anticorpos monoclonais para tratamento de câncer | |
| JP2019527706A5 (enExample) | ||
| JP2015214582A5 (enExample) | ||
| JP2017505782A5 (enExample) | ||
| JP2018531274A5 (ja) | 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗ＳＩＲＰａ化合物 | |
| RU2019106663A (ru) | Комбинированная терапия рака | |
| JP2019506403A5 (enExample) | ||
| JP2015534578A5 (enExample) | ||
| HK1259253A1 (zh) | 用於治疗癌症的ox40激动剂和4-1bb激动剂单克隆抗体的组合 | |
| WO2015097621A3 (en) | Pharmaceutical combinations | |
| JP2016510028A5 (enExample) | ||
| RU2017105425A (ru) | Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины | |
| NZ724368A (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| Lin et al. | Combination treatment including targeted therapy for advanced hepatocellular carcinoma | |
| JP2009505676A5 (enExample) | ||
| RU2016150650A (ru) | Комбинированная терапия для лечения рака |